Lipid Metabolism Practice Questions

Q: What is the rate-limiting step in cholesterol synthesis?

Formation of mevalonate from -hydroxy--methylglutaryl CoA (HMG-CoA). **Explanation:** The correct answer is **A**. Cholesterol synthesis occurs primarily in the cytosol and endoplasmic reticulum of hepatocytes. The committed and rate-limiting step is the reduction of **HMG-CoA to Mevalonate**, catalyzed by the enzyme **HMG-CoA Reductase**. This reaction requires 2 molecules of NADPH as a reducing agent. This step is highly regulated by hormonal control (insulin activates, glucagon inhibits) and feedback inhibition by cholesterol levels. **Analysis of Incorrect Options:** * **Option B:** The formation of malonyl-CoA from acetyl-CoA is the rate-limiting step of **De novo Fatty Acid Synthesis**, catalyzed by **Acetyl-CoA Carboxylase (ACC)**. * **Option C:** The conversion of L-methylmalonyl CoA to succinyl CoA is a step in the **catabolism of odd-chain fatty acids** and certain amino acids (VOMIT: Valine, Odd-chain FAs, Methionine, Isoleucine, Threonine). It requires Vitamin B12. * **Option D:** This is a simple digestive process occurring in the small intestine via the enzyme **Lactase**; it is not part of endogenous lipid biosynthesis. **NEET-PG High-Yield Pearls:** * **Pharmacology Link:** **Statins** (e.g., Atorvastatin) are competitive inhibitors of HMG-CoA Reductase, making this the most clinically significant step in lipid metabolism. * **Subcellular Location:** HMG-CoA Reductase is an integral membrane protein of the **Endoplasmic Reticulum (ER)**, though the reaction products move into the cytosol. * **Differentiation:** Do not confuse this with mitochondrial HMG-CoA Synthase, which is the rate-limiting step for **Ketogenesis**.

Q: HMG CoA production in the liver is inhibited by which hormone?

Insulin. **Explanation:** The production of **HMG-CoA** (3-hydroxy-3-methylglutaryl-CoA) is a central step in both ketogenesis and cholesterol synthesis. In the liver, HMG-CoA is primarily synthesized by the enzyme **HMG-CoA Synthase**. **Why Insulin is Correct:** Insulin is an anabolic hormone that promotes energy storage and lipid synthesis. In the context of **ketogenesis**, insulin acts as a potent inhibitor. It suppresses the mobilization of free fatty acids from adipose tissue (by inhibiting hormone-sensitive lipase) and downregulates the expression of the mitochondrial HMG-CoA synthase gene. Therefore, in the fed state (high insulin), HMG-CoA production for ketone bodies is significantly inhibited. **Why the other options are incorrect:** * **Glucagon:** This is a catabolic hormone. During fasting, glucagon stimulates HMG-CoA synthase and ketogenesis to provide an alternative fuel source for the brain. * **Thyroxine:** Thyroid hormones generally increase metabolic rate and stimulate various pathways of lipid metabolism, including cholesterol synthesis, rather than inhibiting HMG-CoA production. * **Cortisol:** As a stress hormone, cortisol promotes lipolysis and provides substrates for ketogenesis, typically favoring the production of HMG-CoA during prolonged fasting or stress. **High-Yield Clinical Pearls for NEET-PG:** * **Two Locations:** HMG-CoA is produced in the **cytosol** for cholesterol synthesis and in the **mitochondria** for ketogenesis. * **Rate-Limiting Enzymes:** HMG-CoA **Reductase** is the rate-limiting step for cholesterol synthesis (inhibited by Statins), while mitochondrial HMG-CoA **Synthase** is the rate-limiting step for ketogenesis. * **Hormonal Regulation:** Insulin dephosphorylates (activates) HMG-CoA Reductase but inhibits the ketogenic pathway.

Q: Which of the following oils contains the highest percentage of monounsaturated fatty acids (MUFA)?

Groundnut oil. **Explanation:** The question tests the knowledge of fatty acid composition in common dietary fats, a high-yield topic in lipid metabolism. **1. Why Groundnut Oil is Correct:** Groundnut (Peanut) oil is characterized by a high content of **Monounsaturated Fatty Acids (MUFA)**, primarily **Oleic acid (C18:1)**. It typically contains about **40–50% MUFA**, making it one of the richest vegetable sources of these heart-healthy fats among the given options. MUFAs are preferred in diets as they help lower LDL (bad cholesterol) without significantly reducing HDL (good cholesterol). **2. Analysis of Incorrect Options:** * **Soybean oil:** This is predominantly rich in **Polyunsaturated Fatty Acids (PUFA)**, specifically Linoleic acid (Omega-6). While healthy, its MUFA content is lower than groundnut oil. * **Margarine:** This is a processed solid fat produced by the partial hydrogenation of vegetable oils. It is notorious for containing **Trans-fatty acids** and saturated fats, rather than being a primary source of MUFA. * **Palm oil:** This is a tropical oil high in **Saturated Fatty Acids (SFA)**, particularly Palmitic acid (~45-50%). It is often used in the industry due to its stability but is less healthy than MUFA-rich oils. **Clinical Pearls for NEET-PG:** * **Highest MUFA source:** Olive oil (~70-75%) is the gold standard, followed by Groundnut oil and Mustard oil. * **PUFA vs. MUFA:** PUFAs (like those in Safflower/Sunflower oil) are more prone to lipid peroxidation (rancidity) compared to MUFAs. * **Essential Fatty Acids (EFA):** Remember that Linoleic (ω-6) and Linolenic (ω-3) acids are EFAs because humans lack the enzymes to introduce double bonds beyond carbon 9. * **P/S Ratio:** A healthy diet should maintain a balanced Polyunsaturated to Saturated fat ratio (ideally 0.8 to 1.0).

Q: Scavenger receptors uptake:

LDL. ### Explanation **Correct Option: C (LDL)** Scavenger receptors (specifically **Scavenger Receptor Class A or SR-A**) are primarily located on the surface of macrophages. Unlike the regulated LDL-receptor (Apo B-100/E receptor), scavenger receptors are **not down-regulated** by high intracellular cholesterol levels. They recognize and internalize **modified LDL**, such as **oxidized LDL (oxLDL)**. When macrophages take up excessive amounts of oxidized LDL via these receptors, they transform into **foam cells**, which are the hallmark of early atherosclerotic plaque formation. **Analysis of Incorrect Options:** * **A (HDL):** HDL is taken up by **SR-B1** (Scavenger Receptor class B type 1) in the liver and steroidogenic tissues for reverse cholesterol transport. However, in the context of standard "Scavenger Receptors" in pathology/biochemistry exams, the term typically refers to the macrophage receptors involved in atherogenesis (SR-A). * **B & D (VLDL & IDL):** These are triglyceride-rich lipoproteins. VLDL is cleared by the liver via LDL-receptors (recognizing Apo E), and IDL is either converted to LDL or taken up by the liver. They are not the primary ligands for the scavenger receptor pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Foam Cells:** Macrophages + Oxidized LDL = Foam cells (Initial step of atherosclerosis). * **Regulation:** The LDL-receptor is regulated by **SREBP** (Sterol Regulatory Element-Binding Protein), but the Scavenger Receptor is **constitutively active** (unregulated), leading to massive cholesterol accumulation. * **Tangier Disease:** Due to a defect in **ABCA1** transporter, leading to near-zero HDL levels and orange tonsils. * **Wolman Disease:** Deficiency of lysosomal acid lipase, leading to accumulation of cholesteryl esters and triglycerides.

Q: Which of the following occurs in the lipidosis known as Tay-Sachs disease?

Ganglioside GM2 is not catabolized by lysosomal enzymes. **Explanation:** **Tay-Sachs Disease** is a lysosomal storage disorder (specifically a GM2 gangliosidosis) caused by a deficiency of the enzyme **Hexosaminidase A**. 1. **Why Option D is Correct:** Under normal physiological conditions, Hexosaminidase A degrades Ganglioside GM2 into GM3. In Tay-Sachs, the absence of this enzyme prevents the catabolism (breakdown) of **Ganglioside GM2**. Consequently, GM2 accumulates to toxic levels within the lysosomes of neurons, leading to progressive neurodegeneration. 2. **Analysis of Incorrect Options:** * **Option A:** The pathology is due to a failure in **degradation**, not an excess in synthesis. The rate of ganglioside production remains normal. * **Option B:** Xanthomas are characteristic of Hyperlipidemias (e.g., Familial Hypercholesterolemia), where there is an accumulation of cholesterol/LDLs, not gangliosides. * **Option C:** Phosphoglycerides are major components of cell membranes but are not the primary storage material in Tay-Sachs. The specific lipid involved is a sphingolipid (Ganglioside GM2). **High-Yield Clinical Pearls for NEET-PG:** * **Enzyme Deficient:** Hexosaminidase A (Mnemonic: Tay-Sa**X** lacks He**X**osaminidase). * **Accumulated Substance:** GM2 Ganglioside. * **Clinical Triad:** Progressive neurodegeneration, developmental delay, and a **Cherry-red spot** on the macula. * **Distinguishing Feature:** Unlike Niemann-Pick disease, there is **NO hepatosplenomegaly** in Tay-Sachs. * **Histology:** "Onion-skin" appearance of lysosomes under electron microscopy. * **Genetics:** Autosomal Recessive; high prevalence in Ashkenazi Jews.

Q: What is considered the 'good' cholesterol?

HDL (High-Density Lipoprotein). **Explanation:** **HDL (High-Density Lipoprotein)** is known as the "good cholesterol" primarily due to its role in **Reverse Cholesterol Transport (RCT)**. HDL picks up excess cholesterol from peripheral tissues and blood vessel walls (including atherosclerotic plaques) and transports it back to the liver for excretion in bile. This process prevents lipid accumulation in the arteries, thereby exerting a cardioprotective effect. **Analysis of Incorrect Options:** * **LDL (Low-Density Lipoprotein):** Known as "bad cholesterol." It transports cholesterol from the liver to peripheral tissues. High levels lead to cholesterol deposition in arterial walls, forming plaques (atherosclerosis). * **VLDL (Very-Low-Density Lipoprotein):** Secreted by the liver to transport endogenous triglycerides to peripheral tissues. High levels are associated with an increased risk of cardiovascular disease. * **IDL (Intermediate-Density Lipoprotein):** Formed during the degradation of VLDL. It is a precursor to LDL and is also considered pro-atherogenic. **High-Yield NEET-PG Pearls:** * **ApoA-I** is the major apoprotein associated with HDL. * **LCAT (Lecithin-Cholesterol Acyltransferase)** is the enzyme activated by ApoA-I that esterifies cholesterol within HDL, allowing it to be packed into the core. * **CETP (Cholesterol Ester Transfer Protein)** facilitates the exchange of cholesterol esters from HDL for triglycerides from VLDL/LDL. * **Tangier Disease** is a rare genetic disorder characterized by a deficiency in the ABCA1 transporter, leading to near-zero levels of HDL and orange-colored tonsils.

Q: A 30-year-old male patient presents with swellings resembling grapes that have increased in size. He also complains of yellowish pigmentation of the creases of his palms. His fasting lipid profile reveals elevated cholesterol and triacylglycerol levels. What is the diagnosis?

Familial dysbetalipoproteinemia. ### Explanation **Correct Answer: D. Familial dysbetalipoproteinemia (Type III Hyperlipoproteinemia)** **1. Why it is correct:** Familial dysbetalipoproteinemia is characterized by a deficiency or polymorphism in **Apolipoprotein E (Apo E2/E2 isoform)**. Apo E is essential for the hepatic uptake of chylomicron remnants and VLDL remnants (IDL). Its deficiency leads to the accumulation of these "broad-beta" lipoproteins in the blood, causing a simultaneous rise in both **cholesterol and triglycerides**. The pathognomonic clinical sign is **Palmar Xanthomas** (yellowish pigmentation/discoloration of palmar creases). The "grape-like" swellings described are **Tuberous Xanthomas**, which are commonly seen over the elbows and knees in this condition. **2. Why other options are incorrect:** * **A. Familial Chylomicronemia (Type I):** Caused by LPL or Apo C-II deficiency. It presents with eruptive xanthomas and milky plasma, but primarily involves massive elevation of triglycerides, not cholesterol. Palmar xanthomas are absent. * **B. Familial Defective Apo B:** This involves a mutation in Apo B-100, leading to impaired LDL uptake. It mimics Familial Hypercholesterolemia (Type IIa), where only cholesterol is significantly elevated, and tendon xanthomas are more common. * **C. Sitosterolemia:** A rare plant sterol storage disease. While it causes xanthomas, it does not typically present with the classic palmar crease pigmentation seen in Type III. **3. High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** Autosomal Recessive (Apo E2/E2 genotype). * **Lipid Profile:** Elevated IDL (Intermediate Density Lipoprotein). * **Classic Triad:** Palmar xanthomas + Tuberous xanthomas + Premature Atherosclerosis. * **Electrophoresis:** Shows a "Broad Beta Band." * **Treatment:** Fibrates are the first-line treatment as they effectively lower VLDL and IDL.

Q: Which of the following is quantitatively the major contributor to routine clinical measurements of circulating plasma cholesterol concentrations?

Low-density lipoproteins (LDLs). **Explanation:** The correct answer is **Low-density lipoproteins (LDLs)** because they serve as the primary carriers of cholesterol in the systemic circulation. Approximately **70% of the total plasma cholesterol** is transported within LDL particles, which deliver cholesterol to peripheral tissues via LDL receptors. Consequently, in a routine clinical lipid profile, the "Total Cholesterol" measurement is most heavily influenced by the LDL fraction. **Analysis of Options:** * **Chylomicrons:** These are the largest lipoproteins but primarily transport **exogenous (dietary) triglycerides**, not cholesterol. In a fasting state (when clinical samples are usually taken), chylomicrons should be absent from the plasma. * **High-density lipoproteins (HDLs):** While HDL is known as "good cholesterol" because it mediates reverse cholesterol transport, it typically accounts for only **20–30%** of total plasma cholesterol. * **Intermediate-density lipoproteins (IDLs):** These are transient metabolic intermediates formed during the conversion of VLDL to LDL. Under normal physiological conditions, their concentration in the plasma is very low. **High-Yield NEET-PG Pearls:** * **Friedewald Formula:** Used to estimate LDL cholesterol: $LDL = Total\ Cholesterol – (HDL + TG/5)$. This formula is invalid if Triglycerides (TG) are $>400\ mg/dL$. * **Apolipoprotein B-100:** The characteristic structural protein found in VLDL, IDL, and LDL. * **Rate-limiting step:** HMG-CoA reductase is the key enzyme in cholesterol synthesis and the target of Statin drugs. * **Atherogenic potential:** LDL is the most atherogenic lipoprotein because it is small enough to enter the arterial intima and undergo oxidation.

Q: In Familial hypercholesterolemia, which of the following is primarily affected?

LDL receptor. **Explanation:** **Familial Hypercholesterolemia (FH)** is an autosomal dominant disorder characterized by significantly elevated plasma levels of Low-Density Lipoprotein (LDL) cholesterol. **1. Why Option A is Correct:** The primary defect in FH is a mutation in the **LDL receptor (LDLR) gene**. Under normal conditions, the LDL receptor on the liver surface binds to Apo B-100 on LDL particles to facilitate their endocytosis. A deficiency or dysfunction of these receptors leads to decreased clearance of LDL from the blood, resulting in severe hypercholesterolemia and premature atherosclerosis. (Note: Mutations in *Apo B-100* or *PCSK9* can also cause FH, but LDLR mutation is the most common cause). **2. Why Incorrect Options are Wrong:** * **Apo protein A:** This is the primary protein component of **HDL** (the "good" cholesterol). Deficiencies are associated with Tangier disease, not FH. * **Apo protein C:** Apo C-II is a cofactor for Lipoprotein Lipase (LPL). Deficiency leads to **Type I Hyperlipoproteinemia** (Familial Chylomicronemia Syndrome), characterized by high triglycerides, not isolated high LDL. * **Lipoprotein lipase (LPL):** LPL deficiency also leads to **Type I Hyperlipoproteinemia**, resulting in massive elevation of chylomicrons and triglycerides. **3. High-Yield Clinical Pearls for NEET-PG:** * **Classification:** FH is classified as **Fredrickson Type IIa Hyperlipoproteinemia**. * **Clinical Features:** Look for **Tendon Xanthomas** (especially the Achilles tendon) and **Xanthelasmas** (eyelids). * **Genetics:** Homozygous individuals present in childhood with myocardial infarction; Heterozygous individuals typically present in their 30s-40s. * **Treatment:** Statins are the first-line treatment (they upregulate the expression of remaining functional LDL receptors).

Question 1

What is the rate-limiting step in cholesterol synthesis?

Accepted Answer

Formation of mevalonate from -hydroxy--methylglutaryl CoA (HMG-CoA)

Answer

Formation of malonyl CoA from acetyl-CoA

Answer

Conversion of L-methylmalonyl CoA to succinyl CoA

Answer

Hydrolysis of lactose to glucose and galactose

Question 2

HMG CoA production in the liver is inhibited by which hormone?

Accepted Answer

Insulin

Answer

Thyroxine

Answer

Glucagon

Answer

Cortisol

Question 3

Which of the following oils contains the highest percentage of monounsaturated fatty acids (MUFA)?

Accepted Answer

Groundnut oil

Answer

Soybean oil

Answer

Margarine

Answer

Palm oil

Question 4

Scavenger receptors uptake:

Accepted Answer

LDL

Answer

HDL

Answer

VLDL

Answer

IDL

Question 5

Which of the following occurs in the lipidosis known as Tay-Sachs disease?

Accepted Answer

Ganglioside GM2 is not catabolized by lysosomal enzymes

Answer

Synthesis of a specific ganglioside is excessive

Answer

Xanthomas due to cholesterol deposition are observed

Answer

Phosphoglycerides accumulate in the brain

Question 6

What is considered the 'good' cholesterol?

Accepted Answer

HDL (High-Density Lipoprotein)

Answer

LDL (Low-Density Lipoprotein)

Answer

VLDL (Very-Low-Density Lipoprotein)

Answer

IDL (Intermediate-Density Lipoprotein)

Question 7

A 30-year-old male patient presents with swellings resembling grapes that have increased in size. He also complains of yellowish pigmentation of the creases of his palms. His fasting lipid profile reveals elevated cholesterol and triacylglycerol levels. What is the diagnosis?

Accepted Answer

Familial dysbetalipoproteinemia

Answer

Familial chylomicronemia syndrome

Answer

Familial defective apo B

Answer

Sitosterolemia

Question 8

Which of the following is quantitatively the major contributor to routine clinical measurements of circulating plasma cholesterol concentrations?

Accepted Answer

Low-density lipoproteins (LDLs)

Answer

Chylomicrons

Answer

High-density lipoproteins (HDLs)

Answer

Intermediate-density lipoproteins (IDLs)

Question 9

Which of the following enzymes does not participate in fatty acid synthesis?

Accepted Answer

Dehydrogenase

Answer

Hydratase

Answer

Reductase

Answer

Transacylase

Question 10

In Familial hypercholesterolemia, which of the following is primarily affected?

Accepted Answer

LDL receptor

Answer

Apo protein A

Answer

Apo protein C

Answer

Lipoprotein lipase

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?